|
Model Number FR995 |
Device Problem
Device Operates Differently Than Expected (2913)
|
Patient Problems
Calcium Deposits/Calcification (1758); Cardiomyopathy (1764); Stroke/CVA (1770); Congestive Heart Failure (1783); Death (1802); Endocarditis (1834); Thrombus (2101); No Code Available (3191)
|
Event Date 05/23/2015 |
Event Type
Death
|
Event Description
|
Medtronic received information that eleven years, six months post implant of this aortic bioprosthetic valve, this patient experienced a stroke.The patient's physician stated it was not clear whether the stroke was directly attributed to this valve.An echocardiogram showed a mass connected to the valve on the left ventricle.The echocardiographer reported differential diagnoses of mass include vegetation of endocarditis, and less likely thrombus, calcification, myxoma, fibroblastoma or tumor.A blood culture showed no growth after five days.It was also reported that the valve was insufficiently sealing.The patient subsequently expired.The cause of death was provided as septic emboli, endocarditis, cerebrovascular accident (cva), cirrhosis, congestive heart failure (chf) and cardiomyopathy.The physician reported that the valve caused or contributed to the death.
|
|
Manufacturer Narrative
|
The device expiration and manufacturing dates have been added.
|
|
Manufacturer Narrative
|
Date of event is an approximate date.The device has not been returned.Without return of the product, no definitive conclusions can be drawn regarding the clinical observation.Should the device be returned or additional information become available, a supplemental report will be submitted.(b)(4).
|
|
Manufacturer Narrative
|
Conclusion: the device history record was reviewed and showed that this product met all manufacturing specifications for product released for distribution.No issues were identified that would have impacted this event.A variety of factors can influence the onset of stroke, and a conclusive cause could not be determined from the limited information available.In addition a relationship between the device and the death also could not be established.The sterilization process used by medtronic has an anti-microbial kill on the microorganisms, and has demonstrated the ability to inactivate the biological indicator which is representative bioburden for the microbial flora found in our manufacturing controlled environment.Also, this event the occurrence of endocarditis was greater than 12 months post implant.Based on the descriptive comments outlined from the journal literature, complaints which occurred greater than 12 months post implant were largely considered to be community acquired (refer to note 1 below).Therefore, it was unlikely that the endocarditis originally came from the device and/or manufacturing valve process.The organism was not provided and blood cultures showed no growth after five days.Without the return of the valve, a root cause of the regurgitation was unable to be determined.(b)(4).
|
|
Manufacturer Narrative
|
No eval explain code.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Search Alerts/Recalls
|
|
|